Selected research
Industry Research
Platinum-based Antineoplastic Industry Research Report 2026
Market perspective
The global Platinum-based Antineoplastic market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Platinum-based Antineoplastic is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Platinum-based Antineoplastic is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Platinum-based Antineoplastic is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Platinum-based Antineoplastic include ChiTaiTianQing Pharmaceutical Group, Simcere Pharmaceutical, CSPC Pharmaceutical Group, Sanofi, Novartis, MSD, Roche, Pfizer and Hengrui Medicine, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Platinum-based Antineoplastic market in terms of revenue (US$ million) and, where applicable, sales volume (Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Platinum-based Antineoplastic Market by Company
ChiTaiTianQing Pharmaceutical Group
Simcere Pharmaceutical
CSPC Pharmaceutical Group
Sanofi
Novartis
MSD
Roche
Pfizer
Hengrui Medicine
Hansoh Pharmaceutical Group
GSK
Bristol-Myers Squibb
Abbvie
AstraZeneca
Asta Medica GmbH
Platinum-based Antineoplastic Segment by Type
Oxaliplatin
Cycloplatin
Carboplatin
Lobaplatin
Nedaplatin
Cisplatin
Platinum-based Antineoplastic Segment by Application
Targeted Therapy
Monotherapy
Combination Therapy
Platinum-based Antineoplastic Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Platinum-based Antineoplastic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Platinum-based Antineoplastic and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Platinum-based Antineoplastic.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Platinum-based Antineoplastic manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Platinum-based Antineoplastic by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Platinum-based Antineoplastic in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oxaliplatin
- Cycloplatin
- Carboplatin
- Lobaplatin
- Nedaplatin
- Cisplatin
Applications
- Targeted Therapy
- Monotherapy
- Combination Therapy
Companies covered
- ChiTaiTianQing Pharmaceutical Group
- Simcere Pharmaceutical
- CSPC Pharmaceutical Group
- Sanofi
- Novartis
- MSD
- Roche
- Pfizer
- Hengrui Medicine
- Hansoh Pharmaceutical Group
- GSK
- Bristol-Myers Squibb
- Abbvie
- AstraZeneca
- Asta Medica GmbH
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Platinum-based Antineoplastic Market Size (2021-2032)
- 2.2.2 Global Platinum-based Antineoplastic Sales (2021-2032)
- 2.2.3 Global Platinum-based Antineoplastic Market Average Price (2021-2032)
- 2.3 Platinum-based Antineoplastic by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Oxaliplatin
- 2.3.3 Cycloplatin
- 2.3.4 Carboplatin
- 2.3.5 Lobaplatin
- 2.3.6 Nedaplatin
- 2.3.7 Cisplatin
- 2.4 Platinum-based Antineoplastic by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Targeted Therapy
- 2.4.3 Monotherapy
- 2.4.4 Combination Therapy
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Platinum-based Antineoplastic Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Platinum-based Antineoplastic Sales (Units) of Manufacturers (2021-2026)
- 3.3 Global Platinum-based Antineoplastic Revenue of Manufacturers (2021-2026)
- 3.4 Global Platinum-based Antineoplastic Average Price by Manufacturers (2021-2026)
- 3.5 Global Platinum-based Antineoplastic Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Platinum-based Antineoplastic, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Platinum-based Antineoplastic, Product Type & Application
- 3.8 Global Manufacturers of Platinum-based Antineoplastic, Established Date
- 3.9 Global Platinum-based Antineoplastic Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 ChiTaiTianQing Pharmaceutical Group
- 4.1.1 ChiTaiTianQing Pharmaceutical Group Company Information
- 4.1.2 ChiTaiTianQing Pharmaceutical Group Business Overview
- 4.1.3 ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio
- 4.1.5 ChiTaiTianQing Pharmaceutical Group Recent Developments
- 4.2 Simcere Pharmaceutical
- 4.2.1 Simcere Pharmaceutical Company Information
- 4.2.2 Simcere Pharmaceutical Business Overview
- 4.2.3 Simcere Pharmaceutical Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Simcere Pharmaceutical Platinum-based Antineoplastic Product Portfolio
- 4.2.5 Simcere Pharmaceutical Recent Developments
- 4.3 CSPC Pharmaceutical Group
- 4.3.1 CSPC Pharmaceutical Group Company Information
- 4.3.2 CSPC Pharmaceutical Group Business Overview
- 4.3.3 CSPC Pharmaceutical Group Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 CSPC Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio
- 4.3.5 CSPC Pharmaceutical Group Recent Developments
- 4.4 Sanofi
- 4.4.1 Sanofi Company Information
- 4.4.2 Sanofi Business Overview
- 4.4.3 Sanofi Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sanofi Platinum-based Antineoplastic Product Portfolio
- 4.4.5 Sanofi Recent Developments
- 4.5 Novartis
- 4.5.1 Novartis Company Information
- 4.5.2 Novartis Business Overview
- 4.5.3 Novartis Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Novartis Platinum-based Antineoplastic Product Portfolio
- 4.5.5 Novartis Recent Developments
- 4.6 MSD
- 4.6.1 MSD Company Information
- 4.6.2 MSD Business Overview
- 4.6.3 MSD Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 MSD Platinum-based Antineoplastic Product Portfolio
- 4.6.5 MSD Recent Developments
- 4.7 Roche
- 4.7.1 Roche Company Information
- 4.7.2 Roche Business Overview
- 4.7.3 Roche Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Roche Platinum-based Antineoplastic Product Portfolio
- 4.7.5 Roche Recent Developments
- 4.8 Pfizer
- 4.8.1 Pfizer Company Information
- 4.8.2 Pfizer Business Overview
- 4.8.3 Pfizer Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Pfizer Platinum-based Antineoplastic Product Portfolio
- 4.8.5 Pfizer Recent Developments
- 4.9 Hengrui Medicine
- 4.9.1 Hengrui Medicine Company Information
- 4.9.2 Hengrui Medicine Business Overview
- 4.9.3 Hengrui Medicine Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Hengrui Medicine Platinum-based Antineoplastic Product Portfolio
- 4.9.5 Hengrui Medicine Recent Developments
- 4.10 Hansoh Pharmaceutical Group
- 4.10.1 Hansoh Pharmaceutical Group Company Information
- 4.10.2 Hansoh Pharmaceutical Group Business Overview
- 4.10.3 Hansoh Pharmaceutical Group Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Hansoh Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio
- 4.10.5 Hansoh Pharmaceutical Group Recent Developments
- 4.11 GSK
- 4.11.1 GSK Company Information
- 4.11.2 GSK Business Overview
- 4.11.3 GSK Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 GSK Platinum-based Antineoplastic Product Portfolio
- 4.11.5 GSK Recent Developments
- 4.12 Bristol-Myers Squibb
- 4.12.1 Bristol-Myers Squibb Company Information
- 4.12.2 Bristol-Myers Squibb Business Overview
- 4.12.3 Bristol-Myers Squibb Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Bristol-Myers Squibb Platinum-based Antineoplastic Product Portfolio
- 4.12.5 Bristol-Myers Squibb Recent Developments
- 4.13 Abbvie
- 4.13.1 Abbvie Company Information
- 4.13.2 Abbvie Business Overview
- 4.13.3 Abbvie Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Abbvie Platinum-based Antineoplastic Product Portfolio
- 4.13.5 Abbvie Recent Developments
- 4.14 AstraZeneca
- 4.14.1 AstraZeneca Company Information
- 4.14.2 AstraZeneca Business Overview
- 4.14.3 AstraZeneca Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 AstraZeneca Platinum-based Antineoplastic Product Portfolio
- 4.14.5 AstraZeneca Recent Developments
- 4.15 Asta Medica GmbH
- 4.15.1 Asta Medica GmbH Company Information
- 4.15.2 Asta Medica GmbH Business Overview
- 4.15.3 Asta Medica GmbH Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Asta Medica GmbH Platinum-based Antineoplastic Product Portfolio
- 4.15.5 Asta Medica GmbH Recent Developments
5 Global Platinum-based Antineoplastic Market Scenario by Region
- 5.1 Global Platinum-based Antineoplastic Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Platinum-based Antineoplastic Sales by Region: 2021-2032
- 5.2.1 Global Platinum-based Antineoplastic Sales by Region: 2021-2026
- 5.2.2 Global Platinum-based Antineoplastic Sales by Region: 2027-2032
- 5.3 Global Platinum-based Antineoplastic Revenue by Region: 2021-2032
- 5.3.1 Global Platinum-based Antineoplastic Revenue by Region: 2021-2026
- 5.3.2 Global Platinum-based Antineoplastic Revenue by Region: 2027-2032
- 5.4 North America Platinum-based Antineoplastic Market Facts & Figures by Country
- 5.4.1 North America Platinum-based Antineoplastic Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Platinum-based Antineoplastic Sales by Country (2021-2032)
- 5.4.3 North America Platinum-based Antineoplastic Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Platinum-based Antineoplastic Market Facts & Figures by Country
- 5.5.1 Europe Platinum-based Antineoplastic Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Platinum-based Antineoplastic Sales by Country (2021-2032)
- 5.5.3 Europe Platinum-based Antineoplastic Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Platinum-based Antineoplastic Market Facts & Figures by Country
- 5.6.1 Asia Pacific Platinum-based Antineoplastic Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Platinum-based Antineoplastic Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Platinum-based Antineoplastic Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Platinum-based Antineoplastic Market Facts & Figures by Country
- 5.7.1 South America Platinum-based Antineoplastic Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Platinum-based Antineoplastic Sales by Country (2021-2032)
- 5.7.3 South America Platinum-based Antineoplastic Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Platinum-based Antineoplastic Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Platinum-based Antineoplastic Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Platinum-based Antineoplastic Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Platinum-based Antineoplastic Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Platinum-based Antineoplastic Sales by Type (2021-2032)
- 6.1.1 Global Platinum-based Antineoplastic Sales by Type (2021-2032) & (Units)
- 6.1.2 Global Platinum-based Antineoplastic Sales Market Share by Type (2021-2032)
- 6.2 Global Platinum-based Antineoplastic Revenue by Type (2021-2032)
- 6.2.1 Global Platinum-based Antineoplastic Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Platinum-based Antineoplastic Revenue Market Share by Type (2021-2032)
- 6.3 Global Platinum-based Antineoplastic Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Platinum-based Antineoplastic Sales by Application (2021-2032)
- 7.1.1 Global Platinum-based Antineoplastic Sales by Application (2021-2032) & (Units)
- 7.1.2 Global Platinum-based Antineoplastic Sales Market Share by Application (2021-2032)
- 7.2 Global Platinum-based Antineoplastic Revenue by Application (2021-2032)
- 7.2.1 Global Platinum-based Antineoplastic Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Platinum-based Antineoplastic Revenue Market Share by Application (2021-2032)
- 7.3 Global Platinum-based Antineoplastic Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Platinum-based Antineoplastic Value Chain Analysis
- 8.1.1 Platinum-based Antineoplastic Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Platinum-based Antineoplastic Production Mode & Process
- 8.2 Platinum-based Antineoplastic Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Platinum-based Antineoplastic Distributors
- 8.2.3 Platinum-based Antineoplastic Customers
9 Global Platinum-based Antineoplastic Analyzing Market Dynamics
- 9.1 Platinum-based Antineoplastic Industry Trends
- 9.2 Platinum-based Antineoplastic Industry Drivers
- 9.3 Platinum-based Antineoplastic Industry Opportunities and Challenges
- 9.4 Platinum-based Antineoplastic Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst